摘要
根据分层随机原则,将155例Graves病(GD)按所服他巴唑(MMI)剂量不同分为30、15和10mg/d三组。前两组疗效相同,而10mg/d组疗效较慢;每日剂量相同,顿服与分服的疗效相同。后两组的不良反应明显少于30mg/d组。对手术治疗的25例GD的甲状腺内MMI浓度测定,表明15mg/d和30mg/d治疗的甲状腺内浓度差异无显著性;剂量相同,顿服与分服时甲状腺内MMI浓度亦相同。以上结果提示MMI 15mg/d是治疗甲亢的理想剂量,每日一次顿服是合理有效的。
The effects of different dose of methimazole (MMI) and different mode of drug administration were compared in patients with Graves' disease. 155 patients were divided into 5 groups at random: group A 10 mg MMI 3 times daily, group B 30 mg once daily, group C 5 mg 3 times daily, group D 15 mg once daily, group E 10 mg daily. The durations to achieve euthyroidism were not significantly different in group A, B, C and D (3.9± 1.5, 3.8± 1.3, 4.1 ± 1 .6 4.1 ±1.7 weeks respectively), but in group E (7.8±2.1 weeks) it was apparently longer than in other groups. The rate of side-effects occurring in patients treated with 30 mg, 15 mg and 10 mg daily was 37.7%, 14.7% and 5.6% respectively. Intrathyroidal concentrations of MMI were measured by means of high-performance liquid chromalo-graphy in 25 patients who underwent thyroidectomy. There was no difference of MMI concentrations in thyroid glands between the patients treated with 15 mg/d (39.1 ±15.2 μmol/kg) and those with 30 mg/d(42.4± 14.3 μmol/kg), or between the patients receiving the same dose on divided daily dose and single daily dose. These data demonstrate that 15 mg MMI as a single daily dose is reasonable and effective for the treatment of hyperthyroidism.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
1992年第1期17-19,共3页
Chinese Journal of Endocrinology and Metabolism
